ArcticZymes Technologies - Primary insider trading

07 Nov 2024 08:20 CET

(Tromsø 06 November 2024) Frank Mathias, Chairman of the Board has on 06
November purchased 7.000 shares in ArcticZymes Technologies ASA for EUR 1.242
per share. Following this transaction holds Mr. Mathias 7.000 shares in the
company.

Børge Sørvoll, CFO has on 6 November purchased 5.000 shares in ArcticZymes
Technoloiges ASA for NOK 14.00 per share. Following this transaction holds Mr.
Sørvoll 100.428 shares and 280,000 options in the company.

This information is subject to the disclosure requirements in articles 19 of the
Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the
Norwegian Securities Trading Act.

For additional information, please contact
Børge Sørvoll
CFO
+4795290187
ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [AZT] ticker.
Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.
ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com

More information:
Access the news on Oslo Bors NewsWeb site

631520_Notification_trading_Frank_Mathias.pdf
631520_Notification_trading_Borge_Sorvoll1.pdf